Pharmaceutical

Celgene (NASDAQ: CELG) and Acceleron Pharma (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo. As quoted …

Celgene (NASDAQ: CELG) and Acceleron Pharma (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo.

As quoted in the press release:

MEDALIST evaluated the efficacy and safety of luspatercept versus placebo in patients with IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) with chronic anemia and refractory to, intolerant of, or ineligible for treatment with an erythropoietin-stimulating agent (ESA), ring sideroblast-positive and require frequent RBC transfusions.

In addition to achieving the primary endpoint of the study, luspatercept also met the key secondary endpoint of demonstrating a highly statistically significant improvement in RBC transfusion independence of at least 12 consecutive weeks during the first 24 weeks. Modified hematologic improvement-erythroid (IWG mHI-E), a meaningful secondary endpoint, was also achieved.

Adverse events observed in the study were generally consistent with previously published data.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20361.69+75.49
TSXV697.98-2.68
DOW31980.39+51.77
S&P 5003958.94+17.46
NASD11355.39+90.94
ASX7128.80-20.10

COMMODITIES

Commodities
Gold1846.48-20.80
Silver21.89-0.24
Copper4.25-0.05
Palladium2008.00+11.00
Platinum949.50-6.50
Oil109.64-0.13
Heating Oil3.69+0.03
Natural Gas9.20+0.40

DOWNLOAD FREE REPORTS

×